SRTA · Strata Critical Medical, Inc.
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA as a percentage of revenue non-GAAP | 9.5% | Q1 2026 | — |
| Adjusted SG&A as a percentage of revenue non-GAAP | 13.7% | Q1 2026 | — |
| Adjusted EBITDA non-GAAP | 6,955K | Three Months Ended December 31, 2025 | — |
| Adjusted SG&A non-GAAP | 8,922K | Three Months Ended December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SRTA
this stock
Strata Critical Medical, Inc.
|
$440.42M | +5.8% | +34.3% | 8.9 | 4.7% |
|
HCA
HCA Healthcare, Inc.
|
$83.52B | -19.2% | +7.1% | 13.0 | 2.4% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$27.71B | -14.2% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$19.99B | +0.2% | -2.3% | 12.1 | 4.3% |
|
DVA
Davita Inc.
|
$15.04B | +106.2% | +6.5% | 21.9 | 7.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SRTA | -2.7% | -7.6% | +0.4% | -3.4% | +5.8% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | -1.0% | -8.3% | -6.0% | -2.3% | -2.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.